AstraZeneca Contributes to Scientific Dialogue at San Antonio Breast Cancer Symposium


Alisha Martin

As part of its commitment to oncology research, the MedImmune Specialty Care team at AstraZeneca is attending the San Antonio Breast Cancer Symposium (SABCS), beginning on December 10.  Each year, SABCS serves as an international forum for scientists and clinicians to share information and ideas to advance progress against breast cancer.

AstraZeneca helps celebrate 36 years of SABCS.

During the conference, oncology experts will provide updates on the latest strides in the fields of breast cancer research and treatment, and will continue the tradition of scientific exchange established when the symposium was first held in San Antonio in 1978.

Oncology is a core therapy area for AstraZeneca, and we are committed to expanding on our more than 30-year history in this space with continued research in women’s cancers. AstraZeneca is dedicated to understanding the mechanisms behind cancer cell development, and our compounds are represented in more than 10 breast cancer studies being presented at SABCS this year.  We look forward to sharing information with the SABCS community about AstraZeneca’s ongoing research in breast cancer.

From conducting innovative research to offering patient support initiatives, AstraZeneca aims to communicate important findings to the breast cancer community during SABCS and beyond. We recently launched an interactive video resource to help aid the dialogue between health care providers and their patients with metastatic breast cancer (MBC) as well as, a new educational website tailored to the unique needs of women living with MBC. These are some of the many ways AstraZeneca seeks to contribute to solutions in the field of oncology.

Keeping the evolving needs of patients top-of-mind, we look forward to engaging in meaningful dialogue at SABCS with some of the world’s most inspirational leaders in breast cancer.

Click here for information about AstraZeneca’s oncology pipeline. For information about all of the company’s ongoing clinical trials in the United States, visit